{"meta":{"query_hash":"59afb3db9958","filters":{"venue":"PAGEPress (PAGEPress (Italy))"},"cohort_total":2,"direct_labels_cover":0,"predictions_cover":2,"exported":2,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/59afb3db9958","api":"https://metacan.xera.ac/api/v1/cohort?venue=PAGEPress+%28PAGEPress+%28Italy%29%29"},"results":[{"id":"W6981214836","doi":"","title":"DREAMM-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma, including subgroups with renal impairment and high-risk cytogenetics: Session: Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"PAGEPress (PAGEPress (Italy))","topic":"Radiation Effects in Electronics","field":"Engineering","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Discontinuation; Population; Multiple myeloma; Adverse effect; Renal function; Population study; Malignancy","score_opus":0.008847762985695338,"score_gpt":0.1884282021824785,"score_spread":0.17958043919678315,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981214836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879938,0.0014016975,0.007524488,0.00006674903,0.00025484883,0.0016438594,0.00025955762,0.00062136876,0.00023367345],"genre_scores_gemma":[0.99539435,0.00017957797,0.003262703,0.00008793843,0.00022045618,0.00024617658,0.00027336826,0.00030814233,0.00002729577],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99525934,0.0003484612,0.0008870065,0.0012509337,0.0010125788,0.0012416522],"domain_scores_gemma":[0.9972808,0.0007331171,0.00038976246,0.00089023216,0.00013361918,0.00057247124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00034122376,0.0009586856,0.0009093578,0.00032479406,0.00033388074,0.00021895279,0.0005998642,0.0003484221,0.000055074208],"category_scores_gemma":[0.000249307,0.00084699603,0.000110315836,0.0006455811,0.00019533663,0.0006934082,0.00037365707,0.0011346369,0.000028967464],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011274565,0.00048533798,0.5632704,0.00029368608,0.00036849204,0.00013898074,0.0022598272,0.41328198,0.004534668,0.00001147854,0.00027738579,0.013950337],"study_design_scores_gemma":[0.01570527,0.0023014783,0.725992,0.00058104907,0.0002987018,0.000020142912,0.00025050237,0.22327241,0.028666047,0.000029536883,0.0010311003,0.0018517609],"about_ca_topic_score_codex":0.00018527213,"about_ca_topic_score_gemma":0.00036446605,"teacher_disagreement_score":0.19000956,"about_ca_system_score_codex":0.0005484109,"about_ca_system_score_gemma":0.00005937526,"threshold_uncertainty_score":0.99939805},"labels":[],"label_agreement":null},{"id":"W6981310148","doi":"","title":"DREAMM-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma: Session: Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"PAGEPress (PAGEPress (Italy))","topic":"Diverse Scientific and Economic Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"","keywords":"Pembrolizumab; Adverse effect; Multiple myeloma; Interim analysis; Safety profile; Clinical trial","score_opus":0.04391471674687396,"score_gpt":0.24967030587193023,"score_spread":0.20575558912505626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W6981310148","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9899684,0.00039116186,0.0004333005,0.00014094882,0.00035945704,0.0009545674,0.000525496,0.000048747508,0.007177903],"genre_scores_gemma":[0.99835527,0.0001461682,0.000588352,0.000056719182,0.00004553302,0.000047012203,0.00007111933,0.000052564414,0.0006372479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963755,0.00017649282,0.0013657663,0.0013184131,0.00021344949,0.0005503478],"domain_scores_gemma":[0.9973511,0.000726874,0.001061332,0.000549106,0.00010957079,0.0002020259],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001147185,0.0004160498,0.0012469625,0.00031140976,0.000187762,0.000091142305,0.00040298744,0.00022427499,0.00028115598],"category_scores_gemma":[0.00081468886,0.00040189005,0.000120887475,0.000459401,0.00037233921,0.0009029142,0.00044596044,0.00054857356,0.00011051767],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032662933,0.00089915615,0.9856988,0.00012031847,0.00014640234,0.000015643382,0.0018621363,0.0011542686,0.000022906177,0.00025438267,0.0002362004,0.0063234554],"study_design_scores_gemma":[0.018921651,0.0006340368,0.9513239,0.00017034655,0.000036154455,0.00000116441,0.0004936192,0.027245956,0.000110369794,0.00007523156,0.00048036608,0.0005071649],"about_ca_topic_score_codex":0.00046511085,"about_ca_topic_score_gemma":0.0002760595,"teacher_disagreement_score":0.034374896,"about_ca_system_score_codex":0.0001576103,"about_ca_system_score_gemma":0.00004552413,"threshold_uncertainty_score":0.9998433},"labels":[],"label_agreement":null}]}